These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21112077)

  • 41. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
    Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
    Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prophylaxis and von Willebrand's disease (vWD).
    Abshire TC
    Thromb Res; 2006; 118 Suppl 1():S3-7. PubMed ID: 16580053
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epidemiology of inhibitors and current treatment strategies.
    Kreuz W; Ettingshausen CE; Auerswald G; Saguer IM; Becker S; Funk M; Heller C; Klarmann D; Klingebiel T;
    Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges.
    Coppola A; Tagliaferri A; Di Capua M; Franchini M
    Semin Thromb Hemost; 2012 Feb; 38(1):79-94. PubMed ID: 22314606
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimal haemophilia care versus the reality.
    Bolton-Maggs PH
    Br J Haematol; 2006 Mar; 132(6):671-82. PubMed ID: 16487168
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety.
    Lethagen S
    Semin Thromb Hemost; 2003 Feb; 29(1):101-6. PubMed ID: 12640572
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Central venous access devices in patients with hemophilia.
    Valentino LA; Kapoor M
    Expert Rev Med Devices; 2005 Nov; 2(6):699-711. PubMed ID: 16293097
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identifying and overcoming barriers to prophylaxis in the management of haemophilia.
    Petrini P
    Haemophilia; 2007 Sep; 13 Suppl 2():16-22. PubMed ID: 17685919
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel coagulation factor concentrates: issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients.
    Ljung R; Auerswald G; Benson G; Jetter A; Jiménez-Yuste V; Lambert T; Morfini M; Remor E; Sørensen B; Salek SZ
    Haemophilia; 2013 Jul; 19(4):481-6. PubMed ID: 23387528
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Obstetric management of adolescents with bleeding disorders.
    James AH
    J Pediatr Adolesc Gynecol; 2010 Dec; 23(6 Suppl):S31-7. PubMed ID: 20934895
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of inherited von Willebrand disease in 2006.
    Federici AB
    Semin Thromb Hemost; 2006 Sep; 32(6):616-20. PubMed ID: 16977571
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Advances in hemophilia and the role of current and emerging prophylaxis.
    Acharya SS
    Am J Manag Care; 2016 Apr; 22(5 Suppl):s116-25. PubMed ID: 27266808
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Challenges and innovations in the treatment of bleeding disorders.
    DiPaola J; Lillicrap D
    Thromb Res; 2011 Jan; 127 Suppl 1():S1-2. PubMed ID: 21056903
    [No Abstract]   [Full Text] [Related]  

  • 58. Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates.
    Giangrande P; Seitz R; Behr-Gross ME; Berger K; Hilger A; Klein H; Schramm W; Mannucci PM
    Haemophilia; 2014 May; 20(3):322-5. PubMed ID: 24731129
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tranexamic acid without prophylactic factor replacement for prevention of bleeding in hereditary bleeding disorder patients undergoing endoscopy: a pilot study.
    Davis A; Walsh M; McCarthy P; Brown G; Roberts S; Tran H; Street A; Fong CY; Kemp W
    Haemophilia; 2013 Jul; 19(4):583-9. PubMed ID: 23560720
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tertiary prophylaxis in adults: is there a rationale?
    Gringeri A; Lambert T; Street A; Aledort L;
    Haemophilia; 2012 Sep; 18(5):722-8. PubMed ID: 22639786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.